PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Market for POC Molecular Tests Boosted by Discovery of New Disease Markers - As developers of point of care (POC) molecular tests enhance their application scope to detect new disease markers, the POC molecular diagnostics market will present attractive opportunities
Market for POC Molecular Tests Boosted by Discovery of New Disease Markers

 

NewswireToday - /newswire/ - London, United Kingdom, 2008/04/14 - As developers of point of care (POC) molecular tests enhance their application scope to detect new disease markers, the POC molecular diagnostics market will present attractive opportunities.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Market participants can enhance the utilization of POC molecular tests by improvising the existing tests and simultaneously focusing on R&D to develop innovative ways of detecting new disease markers.

New analysis from Frost & Sullivan (drugdiscoverytechnologies.frost.com), finds that The Emerging European Molecular POC Testing Markets are dominated by tests for infectious agents detection, especially for sexually transmitted diseases.

If you are interested in a virtual brochure, which provides manufacturers, end users and other industry participants with an overview of the emerging European molecular POC testing markets, then send an email to Patrick Cairns, Corporate Communications, at pcairns_pr[.]frost.com, your full name, company name, title, telephone number, company email address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you by email.

"The industry and academia should collaborate to research new disease markers and market them efficiently," says Frost & Sullivan Research Analyst Gayathry Ramachandran. "Campaigns and awareness programs must be conducted to educate patients and healthcare professionals regarding the benefits of POC tests for infectious disease detection."

The outlook of infectious disease diagnostics will change drastically with the adoption of POC molecular techniques. Infectious disease POC testing is gradually picking up steam, especially as medical authorities are working towards reducing the occurrence and recurrence of these diseases.

Early diagnosis of infectious agents is crucial to reduce the spread and recurrence of infection. By enabling on-the-spot detection of the disease, POC diagnostics facilitates the design of an appropriate treatment at the earliest.

"After the success of HIV testing in POC format, the platform is being increasingly used to detect other sexually transmitted diseases such as chlamydia and gonorrhoeae," notes Ramachandran. "The adoption of these tests at screening centres, community clinics and other decentralised settings will accelerate the growth of POC infectious disease testing."

However, to gain widespread acceptance in the infectious disease segment, molecular POC test companies should enhance patients' awareness of the solution and wean them away from traditional nucleic acid testing in the laboratories. They should also gain healthcare professionals' confidence to widen the base of POC infectious disease testing.

While companies focus on marketing, researchers and universities have been concentrating on developing polymer disposable chips that can perform multiparametric tests at the POC level. This will be a cost-effective solution for the detection of infectious disease agents.

The introduction of additional POC tests for infectious disease detection will facilitate the screening of fatal diseases at public health centres. Market entrants will do well to be aware of this opportunity and introduce relevant technologies and skills into the market.

The Emerging European Molecular POC Testing Markets is part of the Drug Discovery Technologies Growth Partnership Service programme, which also includes research in the following markets: European Molecular Diagnostics Markets, European IVD Market, European Cancer Diagnostic Market and European Primary Care Diagnostics. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan, the Global Growth Consulting Company, partners with clients to accelerate their growth. The company's Growth Partnership Services, Growth Consulting and Career Best Practices empower clients to create a growth focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.

The Emerging European Molecular POC Testing Markets M1F3

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Market for POC Molecular Tests Boosted by Discovery of New Disease Markers

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Patrick Cairns 
+27 18 468 2315 patrick.cairns[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)